Skip to Content
CancersCancers
  • Review
  • Open Access

28 November 2025

24 Pages

Metabolomics-Based Liquid Biopsy for Predicting Clinically Significant Prostate Cancer

,
,
,
,
,
and
1
Department of Internal Medicine, National Taiwan University Hospital and College of Medicine, Taipei 100225, Taiwan
2
Department of Urology and Institute of Clinical Medicine, National Taiwan University College of Medicine and Hospital, Taipei 100233, Taiwan
3
Department of Biochemistry and Molecular Biology, College of Medicine, National Taiwan University, Taipei 100233, Taiwan
4
Department of Biochemistry and Molecular Cell Biology, School of Medicine, College of Medicine, Taipei Medical University, Taipei 11031, Taiwan
This article belongs to the Section Cancer Biomarkers

Simple Summary

Prostate cancer is one of the most common cancers in men, but not all cases are life-threatening. Current blood tests, like the prostate-specific antigen test, often cannot tell the difference between aggressive and non-aggressive forms of the disease. This can lead to unnecessary treatment. Although magnetic resonance imaging can help, they are expensive and interpretations often vary significantly between radiologists. A promising new approach called metabolomics studies small molecules in blood and urine to identify patterns that distinguish serious prostate cancer from indolent forms. This review examines how these metabolic patterns, including pathways and metabolites consistently reported in more than one study, could assist doctors in better detecting aggressive cancer and avoiding overtreatment. Some of these patterns may even predict aggressive disease more accurately than existing tests. While more research is needed to strengthen these findings, this method could help develop noninvasive tests to support risk assessment before biopsy.

Abstract

Prostate cancer (PC) remains a major cause of cancer deaths in men. The serum biomarker prostate-specific antigen (PSA) lacks specificity in distinguishing clinically significant PC (sPC) from insignificant PC (isPC), leading to overdiagnosis and overtreatment. Although magnetic resonance imaging (MRI) improves detection, it is expensive, is time-consuming, and may involve inter-reader discrepancies. Recently, metabolomics, which has a high analytical sensitivity and broad molecular-feature coverage, has emerged as a promising tool to risk-stratify PC. This review examined studies of blood and urine metabolomics for sPC biomarker identification. Significant metabolite changes in sPC patients often involved fatty acid metabolism, sphingolipid metabolism, glycolysis, the citric acid cycle, purine/pyrimidine metabolism, and tyrosine/phenylalanine metabolism. Specifically, more than one study reported increased lactate and phenylalanine levels, along with decreased tyrosine, xanthine, and histidine levels, in sPC patients. Several metabolic panels outperformed serum PSA in predicting sPC, particularly when combined with clinical factors. Among these, two urine-based tests may have higher accuracy in predicting sPC than most current commercially available assays. However, direct comparison between studies may be inappropriate due to methodological heterogeneity, the variability in biospecimen types, inconsistent use of digital rectal examinations, and different sPC definitions and predictive endpoints. Most relevant studies were of small sample size or lacked external validation. Despite these challenges, metabolomics-based liquid biopsies show strong potential for improving sPC detection. Future research should focus on protocol standardization, MRI integration, absolute metabolite quantification, and validation in large and independent cohorts to enhance model credibility.

Article Metrics

Citations

Article Access Statistics

Multiple requests from the same IP address are counted as one view.